Medtechs Must Partner With US Providers As Outcomes Revolution Ramps Up
US hospitals have suddenly started to care economically about the episodes of care that patients receive – an adjustment that requires medtech companies to adapt accordingly. So says ZS Associates in a new report about how companies need to work in step with providers as the transition to outcomes-based care accelerates.
You may also be interested in...
The return of a Republican president to power in last month's US elections showed – for the second time in 2016 – that punditry can be misleading and opinion polls do not always equate with reality. With just a few weeks to President Trump's inauguration, ZS Associates' Brian Chapman gives an early appraisal of how the new administration might view the health care brief in general and the medtech industry in particular.
Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.
Device sales centers are being required to update the government’s product tracking system with sales data under a series of recent changes spurred partly by COVID-19.